[1] VANHERWEGHEM JL, DEPIERREUX M, TIELEMANS C, et al.Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs[J]. Lancet, 1993, 341(8842): 387-391. [2] NG AW, POON SL, HUANG MN, et al.Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia[J]. Science Translational Medicine, 2017, 412(9): 6446. [3] DE BROE ME.On a nephrotoxic and carcinogenic slimming regimen[J]. American Journal of Kidney Diseases, 1999, 33(6): 1171-1173. [4] CHU CX, ZHU GF.Progress in aristoloid nephropathy[J]. Journal of Chinese Patent Medicine(中成药), 2020, 42(9): 2407-2412. [5] GONG SJ.Aristolochic acid and nephrotoxicity[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2004, 1(2): 34-35. [6] STEFANOVIC V, TONCHEVA D, ATANASOVA S, et al.Etiology of balkan endemic nephropathy and associated urothelial cancer[J]. American Journal of Nephrology, 2006, 26(1): 1-11. [7] YANG YL, WANG YL, GUI XJ.Retrospective analysis of rational use of aristolochia manshuriensis[J]. Chin J Mod Appl Pharm(中国现代应用药学), 2020, 37(23): 2925-2931. [8] National Medical Products Administration. Notice on Cancelling the Medicinal Standard of A ristolochia manshuriensis Kom[EB/OL]. (2003-04-01)[2022-08-20]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20030401010101717.html. [9] National Medical Products Administration Notice on Strengthening the Supervision and Management of Six Medicinal Materials and Their Preparations including A ristolochia fangchi[EB/OL]. (2004-08-05)[2022-08-20]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20040805010101598.html. [10] National Food and Drug Administration. List of aristoliferous herbs that may contain aristolochic acid[EB/OL]. (2017-10-30)[2021-04-06]. http://www.sda.gov.cn/WS01/CL1991/215894.html. [11] MARK L, TANYA Z, FRANCIS J, et al.Structure and stability of DNA containing an aristolactam II-dA lesion: implications for the NER recognition of bulky adducts[J]. Nucleic Acids Research, 2012, 40(6): 2759-2770. [12] STIBOROVÁ M, FREI E, BREUER A, et al.Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy[J]. Exp Toxicol Pathol, 1999, 51(4): 421-427. [13] MEI N, ARLT VM, PHILLIPS DH, et al.DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver[J]. Mutation Research, 2006, 602(1): 83-91. [14] SCHMEISER HH, SCHOEPE KB, WIESSLER M.DNA adduct formation of aristolochic acid I and II in vitro and in vivo[J]. Carcinogenesis, 1988, 9(2): 297-303. [15] MA HY, WU JJ, GE GB, et al.Research progress in metabolism and virus process of aristolochic acid[J]. World Science and Technology-Modernization of Traditional Chinese Medicine(世界科学技术-中医药现代化), 2019, 21(2): 182-189. [16] MA YM, WANG YH, SONG MQ, et al.Effect of Huang and Guan Mu on a content of aristolochic acid[J]. Shanxi Journal of Traditional Chinese Medicine(山西中医), 2015, 31(7): 57-58. [17] LIANG Q, XIE M, Ni C, et al.Metabolomics study with astragalus[J]. Journal of Zhejiang University of Traditional Chinese Medicine(浙江中医药大学学报), 2010, 34(1): 42-43. [18] WU JH, LI HX, WU C.Determination of aristolochic acid content in plasma of guided red dispersion and compatibility group by HPLC[J]. Journal of Hubei School of Traditional Chinese Medicine(湖北中医学院学报), 2010, 12(4): 30-32. [19] WU C.Experimental study on the determination of A content of aristolochic acid in the guided red dispersion and its compatibility group by HPLC method[D]. Wuhan: Hubei College of Traditional Chinese Medicine, 2009. [20] ZHANG C, CHEN YP, YANG YF, et al.Protective effects of yishen ruanjian power on renal interstitial fibrosis in chronic aristolochic acid induced nephropathy rat model[J]. Journal of Chinese Integrated Traditional Chinese and Western Medicine(中国中西医结合杂志), 2005, 25(8): 714-718. [21] GUO YC, LI RF, WANG XG, et al.Intervention of ginseng and prednisone on acute nephrotoxicity in rats[J]. Journal of Chinese Integrated Traditional Chinese and Western Medicine(中国中西医结合急救杂志), 2005, 12(5): 292-296. [22] CHEN JL, WU YH, DENG YY, et al.Protection study of tubular epithelial cell damage caused by aristolochic acid[J]. Chinese Journal of Integrated Traditional Chinese and Western Medicine nephropathy(中国中西医结合肾病杂志), 2005, 6(8): 445-448. [23] GU J, QIU Y, LONG SJ.Determination of total aristolochic acid in Guanmutong decoction and effects of rhubarb and Chuanxiong on acute nephrotoxicity in rats induced by Guanmutong[J]. Journal of Traditional Chinese Medicine(中药材), 2005, 28(8): 695-697. [24] ZHANG MF, SHEN YQ, ZHANG YX.Progress in the protection effect and clinical application of glycyrrhizic acid on renal injury[J]. Journal of Modern Medicine and Clinic(现代药物与临床), 2012, 27(6): 655-659. [25] YANG YF.Study on the protection effect of Panax notoginseng total saponin on the kidney damage of cisplatin and aristolochic acid[D]. Nanning: Guangxi Medical University, 2012. [26] WANG X, HAN LW, HE QX, et al.Protection of rhubarb aric acid in toxic renal function injury[J]. Chinese Journal of Pharmacology and Toxicology(中国药理学与毒理学杂志), 2016, 30(10): 1052-1053. [27] SUN XY, SUN QS, JIA LY.Determination of A of arioxine seeds by HPLC[J]. Shenyang Pharmaceutical University(沈阳药科大学学报), 2009, 26(4): 299-302. [28] HOU SH, LI JJ, HAN LT, et al.Determination of aristolochic acid in different medicinal sites[J]. Journal of Hubei University of Chinese Medicine(湖北中医药大学学报), 2018, 20(6): 42-44. [29] ZHANG YM, LI YS, SUN WX, et al.Comparison study of aristolochic acid and its artillery products[J]. Modern Distance Education of Chinese Traditional Chinese Medicine(中国中医药现代远程教育), 2012, 10(6): 154-156. [30] JIANG X, WANG ZM, YOU LS, et al.RP-HPLC measured the content of aristolochic A in different regions[J]. Journal of Traditional Chinese Medicine(中国中药杂志), 2004, 29(5): 28-30. [31] ZHANG CH, CAO R, LI QQ, et al.Comparison of methods[J]. Chinese Journal of Experimental Prescriptions(中国实验方剂学杂志), 2012, 18(10): 149-152. [32] ZHANG Y, XIAO R, HUANG J, et al.HPLC fingerprint analysis before and after istoloid honey in different regions[J]. Chinese Journal of Pharmacy(中国药学杂志), 2017, 52(16): 1397-1402. [33] SUN KX, ZHENG RS, ZHANG SW, et al.Report of cancer incidence and mortality in different areas of China, 2015[J]. China Cancer(中国肿瘤), 2019, 28(1): 1-11. [34] CHEN SZ, DONG YP, WEN W, et al.Thoughts on carcinogen disputes and drug safety of aristoloc[J]. Second Military Medical University(第二军医大学学报), 2021, 42(1): 1-7. [35] JI XJ, FENG GS, CHEN G, et al.Lack of correlation between aristolochic acid exposure and hepatocellular carcinoma[J]. Science China (Life Sciences), 2018, 61(6): 727-728. [36] Chinese Pharmacopoeia Commission.Pharmacopoeia of People’s Republic of China(中华人民共和国药典)[S]. Beijing: China Medical Science Press, 2020. [37] WANG PL, GUO WB, HUANG GR, et al.Berberine-based heterogeneous linear supramolecules neutralized the acute nephrotoxicity of aristolochic acid by the self-assembly strategy[J]. ACS Applied Materials & Interfaces, 2021, 13(28): 32729-32742. [38] ZHANG PF.Clinical significance analysis of neutrotrophil-lymphocyte ratio (NLR) and cancerous neutroils in patients with hepatocellular liver cancer[D]. Nanjing: Nanjing University, 2016. |